1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends

Evolving Technology Platforms in Pharma-Biotech

  • November 2015
  • 87 pages
  • Frost & Sullivan
Report ID: 3467046

Summary

Table of Contents

The road ahead toward precision medicine

The continued development of new treatments associated with the demographic trends and public health considerations is essential. The biopharmaceutical industry is one of the most research intensive sectors in developed nations. Investments are more than USD 125 billion, especially in early stages development phases, including the processes of discovering and developing new medicines.

Biopharmaceutical innovation has played a major role in the improvement of both length and quality of life during the past decade, considerably reducing the disease burden for individuals and the society. Groundbreaking advances in the scientific understanding of the underlying mechanisms of disease are paving the way for precision medicine for the upcoming years. Indeed, the promise of personalized medicine is becoming a reality generating notable improvements in human health and the potential to reduce the socioeconomic burden of disease.

This research service (RS) depicts the current landscape of biopharmaceutical development, focusing on medicines that have progressed beyond early stage development and have recently entered clinical testing in human volunteers or first-in-human studies. The RS also includes:

R&D portfolio and budgetary analysis
Environmental analysis, depicting the key technical challenges, key business challenges, and emerging market needs
Industry best practices and strategic insights, measuring performance, assessment of partnerships and alliances and R&D pipeline by milestones
Strategic evaluation of R&D portfolio

Research Scope

Research Focus

Report coverage and evaluation
The continued development of new treatments associated with the demographic trends and public health considerations is essential. The biopharmaceutical industry is one of the most research intensive sectors in developed nations. Investments are more than USD 125 billion, especially in early stages development phases, including the processes of discovering and developing new medicines. Biopharmaceutical innovation has played a major role in the improvement of both length and quality of life during the past decade, considerably reducing the disease burden for individuals and the society. Groundbreaking advances in the scientific understanding of the underlying mechanisms of disease are paving the way for precision medicine for the upcoming years. Indeed, the promise of personalized medicine is becoming a reality generating notable improvements in human health and the potential to reduce the socioeconomic burden of disease.

This research service (RS) depicts the current landscape of biopharmaceutical development, focusing on medicines that have progressed beyond early stage development and have recently entered clinical testing in human volunteers or firstin-human studies. The RS also includes:
- R&D portfolio and budgetary analysis
- Environmental analysis, depicting the key technical challenges, key business challenges, and emerging market needs
- Industry best practices and strategic insights, measuring performance, assessment of partnerships and alliances and R&D pipeline by milestones
- Strategic evaluation of R&D portfolio

Key Findings
The Biopharmaceutical Landscape
Current behavior of most top-tier biopharmaceutical companies
- The process of developing a new medicine is long and complex, and highly risky in nature due to the possibility of failures at each step in the process. As an overall estimation, an average cost to yield a single FDA-approved drug is approximately USD billion, and the entire research and development and FDA approval process time lasts between and years. Therefore, the need to reduce risk and guarantee efficient results is critical in our times.
- Factors affecting the cost, duration, and uncertainties associated with clinical trials, are continuously challenging the current drug development economic model and need to be noted and overcome. Interdisciplinary work, involving not only scientists from industry, government, and academia developing new tools and methods to improve R&D efficiency and designing new computer-based models and in silico approaches to predict how a candidate drug is absorbed, distributed, and eliminated from the body, but also, financial managers and economists who help to develop better predictive models, is gaining attention in this decade. The underlying goal is to improve the efficiency of the drug development process by narrowing the patient population where the drug has the best chance of success through precision medicine approaches, as well as, by eliminating candidate drugs before risky and costly clinical trials take place.
- Candidate drugs in clinical trials holding better chance of success, and involving a smaller number of clinical trials are expected to contribute to improve safety and efficacy. Accordingly, researchers are collaborating on pre-competitive research in areas such as biomarkers in order to accelerate research progress.
- Most top-tier biopharmaceutical companies have launched their open innovation programs to foster scientific innovation and collaborations worldwide. Broadly, though with some differences from one company to another, these programs consist of the development of opportunities with external collaborators through the free of charge access to the company’s tool compounds to conduct preclinical research in multiple therapeutic areas, evaluating multiple mechanisms of action (MoA). A Material Transfer Agreement is usually signed to protect the interests of both parties.
- Biomanufacturing in novel hubs such as Singapore’s Biopolis and Tuas Biomedical Parks constitutes one of the major trends for top-tier biopharmaceutical companies at present.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Biosimilars Market Access in the U.S.

  • $ 7500
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

The route to a formal US regulatory pathway for biosimilar approval was established with the creation of the Biologics Price Competition and Innovation Act of 2010. However, it took five more years fo ...

Biosimilars Market Access in Psoriasis

  • $ 7500
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriasis market; however, these market leaders face patent expirations and consequent ...

Single-use Bioprocessing Systems Market - Asia Pacific Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • April 2017
  • by Transparency Market Research

Asia Pacific Single-use Bioprocessing System Market: Overview This report on single-use bioprocessing systems market studies the current as well as future prospects of the market in Asia Pacific. The stakeholders ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.